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To escape from the normal limits on proliferative potential, cancer cells must employ a
means to counteract the gradual telomere attrition that accompanies semi-conservative
DNA replication.While the majority of human cancers do this by up-regulating telomerase
enzyme activity, most of the remainder use a homologous recombination-mediated
mechanism of telomere elongation known as alternative lengthening of telomeres (ALT).
Many molecular details of the ALT pathway are unknown, and even less is known regarding
the mechanisms by which this pathway is activated. Here, we review current ﬁndings
about telomere structure in ALT cells, including DNA sequence, shelterin content, and
heterochromatic state. We speculate that remodeling of the telomere architecture may
contribute to the emergence and maintenance of the ALT phenotype.
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INTRODUCTION
The vastmajority of humancancers utilize a telomeremaintenance
mechanism to compensate for the gradual telomere shorten-
ing that accompanies cellular proliferation, and thereby obtain
an unlimited replicative capacity. This can be accomplished by
up-regulation of the ribonucleoprotein telomerase which adds
telomeric repeats onto the ends of linear chromosomes by reverse
transcription of an RNA template molecule (Morin, 1989), or
by the alternative lengthening of telomeres (ALT) pathway (Bryan
et al., 1995). Immortalized human cell lines that utilizeALT exhibit
numerous phenotypic characteristics that are consistent with the
hypothesis that ALT involves homologous recombination (HR)-
mediated DNA copying of a telomeric DNA template (Dunham
et al., 2000). These characteristics include telomere length hetero-
geneity (Bryan et al., 1995, 1997), abundant extrachromosomal
linear and circular telomeric DNA (Ogino et al., 1998; Tokutake
et al., 1998; Cesare and Grifﬁth, 2004; Wang et al., 2004; Henson
et al., 2009; Nabetani and Ishikawa, 2009), an elevated frequency
of telomere-sister chromatid exchange (T-SCE) events (Bechter
et al., 2004; Londono-Vallejo et al., 2004), and the presence of a
speciﬁc subclass of promyelocytic leukemia (PML) nuclear bod-
ies, containing telomeric DNA, shelterin proteins, and HR factors
including Mre11–Rad50–Nbs1 (MRN), termed ALT-associated
PML bodies (APBs; Yeager et al., 1999). The template for synthesis
of new telomeric DNA can be the telomere of a non-homologous
chromosome (Dunham et al., 2000) or telomeric sequences
elsewhere in the same telomere or the telomere of a sis-
ter chromatid (Muntoni et al., 2009), and we speculate that
extrachromosomal telomeric DNA may also act as the copy
template (Henson et al., 2002).
Telomere length maintenance is a characteristic of almost all
cancers. Consequently, there is considerable interest in the use of
telomeremaintenance inhibitors as a broad-spectrum cancer ther-
apy, and telomerase inhibitors have entered clinical trials (Ruden
and Puri, 2012). However, telomerase inhibitors are unlikely
to be effective for ALT tumors, and there is a possibility that
telomerase-positive tumors will become resistant by activating
ALT. This is supported by recent studies showing that telom-
erase extinction inmouse lymphomas results in emergence of ALT
activity and other adaptive responses (Hu et al., 2012). There-
fore successful therapeutic targeting of telomere maintenance
in cancers will encompass the development of ALT inhibitors.
This will be facilitated by insights into the molecular details of
ALT and how this mechanism is activated. Furthermore, the
possibility remains that ALT activity may also exist under nor-
mal physiological conditions, with evidence for the mechanism
seen in the mouse zygote during the early cleavage steps post-
fertilization (Liu et al., 2007), and most recently in the somatic
cells of mice (Neumann et al., 2013). These data suggest that
while some form of ALT activity may constitute a natural aspect
of telomere biology, the mechanism may become dysregulated
during cancer development. Here, we review aspects of nor-
mal telomere function and the current understanding of ALT,
with particular emphasis upon the structural modiﬁcations that
occur to the telomere during the activation and maintenance
of ALT.
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TELOMERE CAPPING FUNCTION
Telomeres contain several kilobases of the repetitive sequence
5′-TTAGGG-3′, which are predominantly double-stranded, but
terminate in a single-stranded 3′ overhang of the G-rich strand
(Moyzis et al., 1988). This terminus can invade upstream duplex
telomeric DNA and anneal to the complementary C-rich strand,
resulting in the formation of a lariat structure known as a telom-
ere loop (t-loop; Grifﬁth et al., 1999). The t-loop is thought to
protect the chromosome by sequestering the free end, thereby
preventing it from being recognized as a break by the DNA dam-
age response (DDR) proteins (de Lange, 2004). Telomeres may
also form other higher order structures such as G-quadruplexes
(Williamson, 1994).
The chromosome end is further protected by telomere-binding
proteins, especially a six-subunit protein complex (consisting
of the proteins TRF1, TRF2, TIN2, POT1, RAP1, and TPP1)
known as shelterin (Palm and de Lange, 2008). The protection
afforded to chromosome ends by the telomeric nucleoprotein
complex is referred to as telomere capping. Telomeres become
uncapped when they undergo excessive shortening, presumably
because they are no longer able to form a protective higher order
structure and/or bind sufﬁcient shelterin and other telomere-
associated proteins, or when telomere-binding proteins such as
TRF2 or POT1 are depleted experimentally (Denchi and de Lange,
2007). Removal of the entire shelterin complex has demonstrated
the complexity of the capping function, which inhibits process-
ing by multiple pathways, including ataxia telangiectasia mutated
(ATM), ATM and Rad3-related (ATR), non-homologous end-
joining (NHEJ), HR, and resection (Sfeir and de Lange, 2012).
Loss of capping function can be recognized by co-localization
of the telomere with various markers of the DDR, such as
phosphorylated histone H2AX (γ-H2AX) and tumor suppressor
p53-binding protein 1 (TP53BP1), which is referred to as a telom-
ere dysfunction-induced focus (TIF; Takai et al., 2003), or byNHEJ
of chromosome ends.
TELOMERE CAPPING FUNCTION IN ALT CELLS
Most ALT cells lack functional p53 and contain remarkably large
numbers of TIFs (Cesare et al., 2009). Although ALT is associated
with a relatively high level of genetic instability (Lovejoy et al.,
2012), this is compatible with continued cell cycling, so it seems
most likely that the TIFs represent an intermediate or transient
state rather than representing fully uncapped telomeres. The TIFs
in ALT cells can be partly suppressed by expression of exogenous
TRF2 in amanner consistent with its ability to inhibit the function
of the DDR protein, ATM. Many of these TIFs occur on telomeres
that are not short, and are not suppressed by lengthening the
shortest telomeres with exogenous telomerase (Cesare et al., 2009).
These observations suggest that ALT cells contain telomeres with
abnormal capping function, and raise the question whether these
abnormalities are actually required for ALT activity.
Alternative lengthening of telomeres cells exhibit a very sub-
stantial increase in T-SCEs, although the rate of HR elsewhere in
the genome is not increased compared to telomerase-positive cells
(Bechter et al., 2003, 2004; Londono-Vallejo et al., 2004). Thus
there appears to be a speciﬁc defect in the ability of the telomere
cap in ALT cells to suppress telomeric HR, and given the proposed
involvement of HR intermediates in ALT-mediated copying of
telomeric template DNA, it is reasonable to speculate that this
cap defect is essential for ALT. This defect does not result from
mutations in KU70, TRF2, POT1, or RAP1 which are all wild-type
and present at normal levels in ALT cells (Lovejoy et al., 2012), so
other explanations must be sought.
TRF2 is of particular interest in the context of telomere cap-
ping in ALT because, in addition to its involvement in suppression
of telomeric HR described previously, it has a role in the for-
mation of t-loops and four-strand DNA junctions, and in the
protection of these structures against enzymatic cleavage. This
suggests that TRF2 may have a role in the regulation of telomeric
recombination by both promoting t-loop formation and prevent-
ing resolution of telomeric recombination intermediates (Stansel
et al., 2002; Fouche et al., 2006; Poulet et al., 2009). In addition,
through its interaction with the helicases BLM andWRN, TRF2 is
also involved in the unwinding of duplex telomericDNA (Opresko
et al., 2002) and potentially in the resolution of aberrant telomeric
structures. The total level of TRF2 in ALT cells is not signiﬁcantly
different from other cells (Lovejoy et al., 2012), but the total quan-
tity of telomeric DNA is signiﬁcantly increased (Lau et al., 2012),
and overexpression of TRF2 is able to suppress the formation of
TIFs (Cesare et al., 2009). These observations suggest that the
amount of TRF2 (and possibly of other shelterin components)
relative to telomeric DNA is decreased in ALT cells, resulting in a
partial functional deﬁciency that may contribute to the prevalence
of intermediate-state TIFs in these cells, and an HR-permissive
telomeric state.
ABNORMAL DNA SEQUENCES IN ALT TELOMERES
Theproximal regions of normal human telomeres are composedof
variant repeats such as TGAGGG, TCAGGG, and TTGGGG (All-
shire et al., 1989; Baird et al., 1995). These regions are hypervari-
able and reﬂect a high underlying mutation rate, predominantly
involving base substitutions and simple intra-allelic expansions
and contractions. Characterization of these events is possible due
to linkage disequilibrium spanning these proximal regions, which
has resulted in the evolution of a limited number of haploid lin-
eages with related telomere sequence maps (Baird et al., 1995).
Variant repeats are usually restricted to the proximal 2 kb of the
telomere (Allshire et al., 1989); however, several studies have indi-
cated that ALT telomeres may contain an abundance of abnormal
DNA sequences. Firstly, the C-circle assay produced higher yields
from some ALT cell lines following inclusion of deoxycytidine
triphosphate (dCTP), indicating the presence of sequences other
than TTAGGG in telomeric C-circles (Henson et al., 2009). In
addition to variant repeats, telomeres of ALT cells are able to
accommodate large amounts of non-telomeric sequences such as
SV40 DNA (Fasching et al., 2005; Marciniak et al., 2005).
We recently used a sequencing approach to show directly that
variant repeats are dispersed throughoutALT telomeres (Conomos
et al., 2012). We propose that this results from the HR-mediated
telomere replication that has previously been shown by telom-
ere mapping experiments to occur in the variant repeat-dense
proximal regions of the telomere (Varley et al., 2002). This can be
predicted to cause a breakdownof linkagedisequilibrium, andulti-
mately the spreading of variant sequences throughout the telomere
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(Figure 1)whichmayhave profound implications for the structure
and function of telomeric nucleoprotein.
One of the consequences of these changes may be to “lock in”
a recombinogenic telomeric state. Telomere exchange events have
been shown to occur at low frequency in normal telomere biol-
ogy (Baird et al., 1995). We hypothesize that these may even more
rarely involve the proximal telomere region, but that the frequency
increases after genetic changes such as loss of p53 suppressor func-
tion. When variant repeats spread from the proximal telomere
region in this way, they may destabilize the telomere in favor of
recombination, resulting in the incorporation of more variant
repeats and permitting further recombination, thereby creating
a positive feedback loop that results in sustained ALT activity. This
hypothesis is supported by telomere mapping analysis of clonal
cell populations derived from an ALT cell line compared to pre-
crisis cells, in which all clones contained a mutant telomere map,
presumably as a result of a single early inter-telomeric recombina-
tion event during clonal expansion following crisis (Varley et al.,
2002). The reason that a change in DNA content may result in
increased telomeric recombinogenicity may lie in its effects on
protein binding.
ALTERED PROTEIN BINDING AT ALT TELOMERES
The shelterin complex binds speciﬁcally to the TTAGGG repeat
sequence by means of the Myb domains in TRF1 and TRF2
which bind duplex telomeric repeats (Court et al., 2005; Hanaoka
et al., 2005), and by sequence-speciﬁc binding of POT1 to single-
stranded telomeric DNA (Loayza et al., 2004). Telomeres present
a challenge to the DNA replication machinery, giving rise to
replication-dependent defects, and they consequently resemble
fragile sites. It is unclear what aspect of telomere structure con-
fers this fragile nature; however, TRF1 is required to prevent
these replication problems (Sfeir et al., 2009). Moreover, TRF2
and POT1 function independently to repress DNA damage signal-
ing and DNA repair pathways (Denchi and de Lange, 2007). The
speciﬁcity of shelterin binding to TTAGGG repeats means that
any sequence perturbations in the telomere are likely to have a
profound impact on shelterin binding.
Variant repeat interspersionnot only disrupts shelterin binding,
but can also be predicted to result in sequence-speciﬁc binding of
other proteins (Figure 2). This is exempliﬁed by the localization of
a group of nuclear receptors to the telomeres of ALT cells (Dejardin
and Kingston, 2009; Conomos et al., 2012) because of their high
binding afﬁnity for the TCAGGG variant repeat (Conomos et al.,
2012). It has been demonstrated experimentally that telomeric
incorporation of TCAGGG repeats directly resulted in recruit-
ment of nuclear receptors, an increased number of TIFs and the
induction of some ALT phenotypic characteristics. It remains to
be determined whether other sequences within ALT telomeres are
similarly responsible for altered protein binding.
EPIGENETIC STATE OF ALT TELOMERIC CHROMATIN
It is possible that aspects of telomere architecture other than
DNA sequence and shelterin binding also contribute to a state
that is permissive for telomeric recombination and ALT activity.
Telomeric chromatin carries histone modiﬁcations characteristic
of transcriptional repression (reviewed inBlasco,2007; Grewal and
Jia, 2007). These include the heterochromatic marks, H3K9me3
FIGURE 1 | HR-mediated telomeric replication in ALT cells. Non-canonical
sequences are present in the proximal 2 kb region of the telomere array in
human cells. Telomeric replication in ALT cells can occur by HR-mediated
inter-telomeric copying of (A) canonical TTAGGG repeats in the telomere
repeat array, or (B) variant or non-canonical repeats present in the proximal
regions of the telomere.
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FIGURE 2 | Remodeling of the telomere architecture during activation
of the ALT mechanism. Non-canonical repeat sequences existing in the
proximal region are distributed throughout the telomere array during ALT
activation (see Figure 1). Hence, there is an insufﬁcient concentration of
shelterin binding sites for telomere capping, causing the telomere to elicit a
DDR, whilst still being able to suppress chromosomal end-to-end fusions
caused by NHEJ. DNA-binding proteins capable of binding speciﬁcally to
these non-canonical sequences are consequently spread throughout the
telomere, increasing its recombinogenicity. These proteins may also be
capable of recruiting various chromatin remodeling complexes which
can alter the telomere architecture further, in favor of telomeric
recombination.
and H4K20me3 (trimethylation of histone H3 at lysine 9 and
of histone H4 at lysine 20), histone hypoacetylation, and the
accumulation of several isoforms of heterochromatin protein 1
(HP1; Garcia-Cao et al., 2004; Benetti et al., 2007a; Michishita
et al., 2008). In addition, subtelomeric regions contain hyper-
methylated DNA (Gonzalo et al., 2006). Repressive chromatin
modiﬁcations are also enriched at subtelomeric repeats (Benetti
et al., 2007a,b), which appears paradoxical given the subtelom-
eric transcriptional origin of telomeric repeat-containing RNA
(TERRA; Azzalin et al., 2007; Schoeftner and Blasco, 2008; Luke
and Lingner, 2009). TERRAhas also been implicated in the regula-
tion of telomere length and telomeric chromatin structure, having
been shown to facilitate heterochromatin formation at telomeres
via recruitment of H3K9me3 and HP1 (Deng et al., 2009), and
in negative feedback regulation of its own transcription (Arnoult
et al., 2012).
The results of several studies predominantly in mice, have sug-
gested that alterations in telomeric chromatin may cause some
phenotypic characteristics of ALT, and may ultimately result in
ALT activity. Manipulation of mouse telomeric and subtelomeric
heterochromatin resulted in a substantially increasednumber of T-
SCEs and telomere elongation (Gonzalo et al., 2006; Benetti et al.,
2007a,b). Furthermore, a number of studies have shown that loss
of telomeric heterochromatic marks in mice leads to an increase
in the number of APBs per cell (Garcia-Cao et al., 2004; Gonzalo
et al., 2006; Benetti et al., 2007a,b, 2008). It has been speculated
that telomeric chromatin can adopt a more open conﬁguration,
thus facilitating HR, ALT-mediated telomere elongation, and APB
formation, although increased telomerase activity due to greater
access of telomerase to the telomere cannot be excluded as the
cause of these alterations. It therefore remains an interesting pos-
sibility that a “closed” telomeric and subtelomeric chromatin state
is involved in repressing the ALTmechanism (Gonzalo et al., 2006;
Benetti et al., 2007a,b).
Decreased subtelomeric DNA methylation, resulting from
mutant DNA methyltransferases, was reported to be associated
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with increased telomeric recombination frequency and telomere
lengthening in mice (Gonzalo et al., 2006). Human telomerase-
positive cell lines showed a negative correlation of subtelomeric
DNA methylation with telomere length and telomere recom-
bination, and treatment of telomerase-positive cell lines with
demethylating drugs caused hypomethylation of subtelomeric
repeats and increased telomere recombination (Vera et al., 2008).
In human ALT cells, however, the relationship between subtelom-
eric DNA methylation and ALT activity is currently unclear. One
study found that the level of subtelomeric DNA methylation was
heterogeneous in human ALT cells, but that on average it was
similar to the level in the non-immortalized cells from which
they were derived, and much less than in telomerase-positive
cell lines (Ng et al., 2009). A caveat to this and other studies of
subtelomeric DNA methylation is that only a small number of
subtelomeric DNA regions at various distances from the telom-
eres were sampled. It has also been observed that ALT cells have
more TERRA than normal cell strains or telomerase-positive cell
lines, even when adjusted for the greatly increased telomeric DNA
content of ALT cells (Ng et al., 2009). Another study found that
there is genome-wide hypomethylationof Alu repeats andpericen-
tromeric Sat2 DNA sequences in ALT-positive human tumor cells,
and that although subtelomeric DNA hypomethylation was fre-
quently present in these cells it was not required forHRmanifested
as T-SCEs (Tilman et al., 2009).
THE ROLE OF CHROMATIN REMODELING FACTORS IN ALT
Circumstantial evidence for an altered epigenetic state in ALT
telomeres was obtained by mass spectrometric analysis of the pro-
tein composition of telomeric chromatin (Dejardin and Kingston,
2009). Numerous chromatin remodeling proteins were found to
be present at the telomeres of anALT cell line butwere not detected
at the telomeres of the telomerase-positive control. Most notably,
a class of nuclear receptors, which bind to variant repeats and are
capable of initiating gene expression changes via recruitment of
chromatin remodelers (Cui et al., 2011), were identiﬁed at ALT
telomeres. It is possible that recruitment of such proteins may
alter the heterochromatic state of ALT telomeres, contributing to
the derepression of telomeric recombination.
Recent studies of ALT tumors and immortalized cell lines
found a strong correlation between telomere maintenance by
ALT and loss of activity of the switch/sucrose non-fermentable
(SWI/SNF) family ATP-dependent helicase (ATRX) or its binding
partner death-associated protein 6 (DAXX; Heaphy et al., 2011;
Bower et al., 2012; Lovejoy et al., 2012; Schwartzentruber et al.,
2012). ATRX and DAXX form a chromatin remodeling complex
that localizes to PML nuclear bodies (Xue et al., 2003), although
the precise mechanism of chromatin remodeling remains elu-
sive. Nevertheless, it has been shown that ATRX and DAXX act
in concert to deliver the histone variant H3.3 to telomeres in
a replication-independent manner (Goldberg et al., 2010; Law
et al., 2010; Lewis et al., 2010). While the purpose of this H3.3
deposition at telomeres is not understood, it has been postu-
lated that inhibition of ATRX/DAXX function may result in the
loss of heterochromatic marks thought to suppress the inherently
recombinogenic nature of repetitive telomeric DNA.
Some ALT tumors, however, have mutations in both H3.3
and a member of the ATRX/DAXX complex (Schwartzentruber
et al., 2012), which indicates that the loss of some function of
ATRX/DAXX other than H3.3 deposition is selected for in ALT
tumors. ATRX also appears to have a function in the repression of
TERRA (Goldberg et al., 2010), which is consistent with the obser-
vation that elevated levels of TERRA exist in many ALT tumors
and cell lines compared to those which have activated telomerase
(Ng et al., 2009; Lovejoy et al., 2012; Sampl et al., 2012). ATRX
depletion in mouse embryonic stem cells has also been shown to
reduce HP1α recruitment to telomeres and to cause an increase in
telomere dysfunction as demonstrated by localization of γ-H2AX
at chromosome ends (Wong et al., 2010). Alternatively, loss of
ATRX/DAXX function may act elsewhere in the genome and lead
to altered gene expression, e.g., by binding to DNA structures
such as G-quadruplexes (Law et al., 2010), thus indirectly effect-
ing changes that promote ALT activity. Nonetheless, depletion of
either ATRX or DAXX failed to activate ALT in SV40-transformed
ﬁbroblasts (Bower et al., 2012; Lovejoy et al., 2012), suggesting that
loss of ATRX/DAXX function alone is not sufﬁcient for ALT to be
initiated.
CONCLUDING REMARKS
In light of the evidence reviewed above we propose that remodel-
ing of the telomeric architecture plays a key role in permitting
sufﬁcient levels of ALT activity to prevent telomere shorten-
ing in ALT cell lines and tumors. Changes in DNA content, in
which variant repeat sequences that occur in the proximal region
of the telomere become spread throughout the telomeres, are
common. This presumably occurs initially via a rare, stochastic
event in which the proximal region is used as a copy template
by a telomere, but the presence of these sequences in a telom-
ere contributes to a state which is permissive to ALT that results
in their spread to other telomeres. Consequences of this altered
DNA content include binding of additional proteins as well as a
decreased relative shelterin content that may lead to secondary
changes in telomeric heterochromatin. Furthermore, other alter-
ations in telomeric chromatin marks may also contribute to the
ALT-permissive state, including changes that may result from loss
of ATRX/DAXX function, which is a common characteristic of the
ALT mechanism.
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